Select Publications

Journal articles

Mwasakifwa GE; Amin J; White CP; Center JR; Kelleher A; Boyd MA, 2020, 'Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE study', HIV Medicine, 21, pp. 492 - 504, http://dx.doi.org/10.1111/hiv.12882

Vannakit R; Andreeva V; Mills S; Cassell MM; Jones MA; Murphy E; Ishikawa N; Boyd MA; Phanuphak N, 2020, 'HIV programmes in countries within the Asia-Pacific region – Authors' reply', The Lancet HIV, 7, pp. e530 - e531, http://dx.doi.org/10.1016/S2352-3018(20)30210-1

Denholm JT; Davis J; Paterson D; Roberts J; Morpeth S; Snelling T; Zentner D; Rees M; O'Sullivan M; Price D; Bowen A; Tong SYC; Anderson S; McQuilton Z; Venkatesh B; Hammond N; Jha V; Burston VJ; McMahon J; Charles P; Commons R; O'Brien D; Mahoney A; Sheffield D; Lim LL; Gardiner B; Schulz T; Torresi J; Chean R; Sasadeusz J; Rogers B; Aboltins C; Singh K; Yong M; Lister D; Visvanathan K; Molton J; Tai A; Chalmers R; Martinello M; Wilson P; Gray T; Coghill S; Foo H; Sud A; Williams J; Lwin N; Post J; Van Haal S; Sullivan R; Matthews G; Kwan BCH; Slack A; Shum O; Cochrane B; Dotel R; Gilbey T; Mina M; Su Y; Trethewy C; Hudson B; Chatterji A; Mostert C; New D; Raby E; Hui S; Robinson O; Hart J; Tan SJ; Arellano A; Chambers J; Davis J; Rafiei N; Smith S; Sehu M; Da Silva J; Griffin P; Henderson A; Chaw K; Choong K; Burke A; Heather C; Senanayake S; Boyd M; Rowe E; Anagnostou M; Trad A; Ratcliff A; Dummer J; Bhally H; Giola M; Grimwade K; Chang CLL; Verrall A; Hogg S; Restropo D; Maze M; Ritchie S; Gedye C; Chang J, 2020, 'The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial', Trials, 21, http://dx.doi.org/10.1186/s13063-020-04576-9

Lau A; Kong FYS; Fairley CK; Templeton DJ; Amin J; Boyd MA; Bradshaw C; Chen MY; Donovan B; Khaw C; Lewis DA; McNulty A; Regan DG; Ratnayake M; Hocking JS, 2020, 'Factors Associated with Early Resumption of Condomless Anal Sex among Men Who Have Sex with Men after Rectal Chlamydia Treatment', Sexually Transmitted Diseases, 47, pp. 389 - 394, http://dx.doi.org/10.1097/OLQ.0000000000001166

Vannakit R; Andreeva V; Mills S; Cassell MM; Jones MA; Murphy E; Ishikawa N; Boyd MA; Phanuphak N, 2020, 'Fast-tracking the end of HIV in the Asia Pacific region: domestic funding of key population-led and civil society organisations', The Lancet HIV, 7, pp. e366 - e372, http://dx.doi.org/10.1016/S2352-3018(20)30077-1

Yang F; Janamnuaysook R; Boyd MA; Phanuphak N; Tucker JD, 2020, 'Key populations and power: people-centred social innovation in Asian HIV services', The Lancet HIV, 7, pp. e69 - e74, http://dx.doi.org/10.1016/S2352-3018(19)30347-9

Khaw C; Malden C; Ratnayake M; Boyd M, 2020, 'Diagnosis and Management of Syphilis in Patients With HIV Co-infection', Current Treatment Options in Infectious Diseases, 12, pp. 215 - 226, http://dx.doi.org/10.1007/s40506-020-00225-6

Melaku YA; Gill TK; Appleton SL; Hill C; Boyd MA; Adams RJ, 2019, 'Sociodemographic, lifestyle and metabolic predictors of all-cause mortality in a cohort of community-dwelling population: An 18-year follow-up of the North West Adelaide Health Study', BMJ Open, 9, http://dx.doi.org/10.1136/bmjopen-2019-030079

Bell SK; Mena G; Dean J; Watts P; Howard C; Boyd M; Gilks C; Gartner C, 2019, 'Addressing smoking among people living with HIV: a cross-sectional survey of Australian HIV health practitioners’ practices and attitudes', AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 31, pp. 436 - 442, http://dx.doi.org/10.1080/09540121.2018.1500007

McManus H; Callander D; Donovan B; Russell DB; O'Connor CC; Davies SC; Lewis DA; Hellard ME; Chen MY; Petoumenos K; Varma R; Cogle A; Boyd MA; Grulich A; Pollard J; Medland N; Fairley CK; Guy RJ, 2019, 'Early initiation of antiretroviral therapy for people newly diagnosed with HIV infection in Australia: trends and predictors, 2004–2015', Medical Journal of Australia, 210, pp. 269 - 275, http://dx.doi.org/10.5694/mja2.50006

Boyd MA; Boffito M; Castagna A; Estrada V, 2019, 'Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps', HIV Medicine, 20, pp. 3 - 11, http://dx.doi.org/10.1111/hiv.12708

Ramachandran J; Kaambwa B; Muller K; Haridy J; Tse E; Tilley E; Waddell V; Gordon D; Shaw D; Nelson R; boyd M; Warner M; Ralton L; Colman A; stewart J; Harding D; Chinnaratha A; Woodman R; Huynh D; Wigg A, 2019, 'FRI-200-Spend less get more;cost effectiveness of various models of care in hepatitis C treatment', Journal of Hepatology, 70, pp. e479 - e479, http://dx.doi.org/10.1016/s0618-8278(19)30945-4

Giles ML; Gartner C; Boyd MA, 2018, 'Smoking and HIV: What are the risks and what harm reduction strategies do we have at our disposal?', AIDS Research and Therapy, 15, http://dx.doi.org/10.1186/s12981-018-0213-z

Haridy J; Wigg A; Muller K; Ramachandran J; Tilley E; Waddell V; Gordon D; Shaw D; Huynh D; Stewart J; Nelson R; Warner M; Boyd M; Chinnaratha MA; Harding D; Ralton L; Colman A; Liew D; Iyngkaran G; Tse E, 2018, 'Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience', Journal of Viral Hepatitis, 25, pp. 1287 - 1297, http://dx.doi.org/10.1111/jvh.12943

Wright E; Grulich A; Roy K; Boyd M; Cornelisse V; Russell D; O'Donnell D; Whittaker B; Crooks L; Zablotska I, 2018, 'Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018.', J Virus Erad, 4, pp. 143 - 159, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892678/

Stockdale AJ; Saunders MJ; Boyd MA; Bonnett LJ; Johnston V; Wandeler G; Schoffelen AF; Ciaffi L; Stafford K; Collier AC; Paton NI; Geretti AM, 2018, 'Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis', Clinical Infectious Diseases, 66, pp. 1846 - 1857, http://dx.doi.org/10.1093/cid/cix1108

Wright E; Grulich A; Roy K; Boyd M; Cornelisse V; Russell D; O'Donnell D; Whittaker B; Crooks L; Zablotska I, 2018, 'Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018.', Journal of Virus Eradication, 4, pp. 143 - 159

Boyd MA; Cooper DA, 2018, 'Combination ART: are two drugs as good as three?', The Lancet, 391, pp. 817 - 819, http://dx.doi.org/10.1016/S0140-6736(18)30008-4

Mwasakifwa GE; Moore C; Carey D; Amin J; Penteado P; Losso M; Lim PL; Mohapi L; Molina JM; Gazzard B; Cooper DA; Boyd M, 2018, 'Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy', AIDS, 32, pp. 357 - 361, http://dx.doi.org/10.1097/QAD.0000000000001688

Yao AH; Moore CL; Lim PL; Molina JM; Madero JS; Kerr S; Mallon PWG; Emery S; Cooper DA; Boyd MA, 2018, 'Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial', Antiviral Therapy, 23, pp. 21 - 32, http://dx.doi.org/10.3851/IMP3171

Boyd MA; Cooper DA; Gilks CF, 2018, 'Towards a universal second-line fixed-dose combination ART', The Lancet HIV, 5, pp. e3 - e5, http://dx.doi.org/10.1016/S2352-3018(17)30180-7

Wright E; Grulich A; Roy K; Boyd M; Cornelisse V; Russell D; O'Donnell D; Whittaker B; Crooks L; Zablotska I, 2018, 'Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018', Journal of Virus Eradication, 4, pp. 143 - 159, http://dx.doi.org/10.1016/s2055-6640(20)30260-0

Haridy J; Wigg A; Muller K; Ramachandran J; Tilley E; Waddell V; Gordon D; Shaw D; Huynh D; Stewart J; Nelson R; Warner M; Boyd M; Chinnaratha A; Harding D; Ralton L; Colman A; Iyngkaran G; Tse E, 2018, 'Outcomes of direct-acting antiviral therapy for chronic hepatitis C following unrestricted access in Australia: Real-world outcomes from the state of South Australia', Journal of Hepatology, 68, pp. S265 - S265, http://dx.doi.org/10.1016/s0168-8278(18)30743-8

Boyd MA; Mocroft A; Ryom L; Monforte AD; Sabin C; El-Sadr WM; Hatleberg CI; De Wit S; Weber R; Fontas E; Phillips A; Bonnet F; Reiss P; Lundgren J; Law M; Han A, 2017, 'Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study', PLoS Medicine, 14, pp. e1002424, http://dx.doi.org/10.1371/journal.pmed.1002424

Puhr R; Petoumenos K; Youds D; Law MG; Templeton DJ; Ellis D; Bloch M; Agrawal S; Vincent T; Allen D; Smith D; Rankin A; Baker D; O'Connor CC; Thackeray O; Jackson E; McCallum K; Ryder N; Sweeney G; Cooper D; Carr A; Macrae K; Hesse K; Finlayson R; Gupta S; Langton-Lockton J; Shakeshaft J; Brown K; Idle S; Arvela N; Varma R; Lu H; Couldwell D; Eswarappa S; Smith DE; Furner V; Cabrera G; Fernando S; Cogle A; Lawrence C; Mulhall B; Boyd M; Law M; Huang R; Han A; Gunathilake M; Payne R; O'Sullivan M; Croydon A; Russell D; Cashman C; Roberts C; Sowden D; Taing K; Marshall P; Orth D; Rowling D; Latch N; Warzywoda E; Dickson B; Donohue W; Moore R; Edwards S; Boyd S; Roth NJ; Lau H; Read T; Silvers J; Zeng W; Hoy J; Watson K; Bryant M; Price S; Woolley I; Giles M; Korman T; Williams J; Nolan D; Allen A; Guelfi G; Mills G; Wharry C; Raymond N; Bargh K, 2017, 'The impact of changes in HIV management guidelines on time to treatment initiation in Australia', HIV Medicine, 18, pp. 701 - 703, http://dx.doi.org/10.1111/hiv.12504

Boyd MA; Cooper DA, 2017, 'Long-acting injectable ART: next revolution in HIV?', The Lancet, 390, pp. 1468 - 1470, http://dx.doi.org/10.1016/S0140-6736(17)31962-1

Thit SS; Aung NM; Htet ZW; Boyd MA; Saw HA; Anstey NM; Kyi TT; Cooper DA; Kyi MM; Hanson JP, 2017, 'The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study.', BMC Medicine, 15, pp. 145, http://dx.doi.org/10.1186/s12916-017-0888-3

Bell SK; Mena G; Dean J; Boyd M; Gilks C; Gartner C, 2017, 'Vaporised nicotine and tobacco harm reduction for addressing smoking among people living with HIV: A cross-sectional survey of Australian HIV health practitioners’ attitudes', Drug and Alcohol Dependence, 177, pp. 67 - 70, http://dx.doi.org/10.1016/j.drugalcdep.2017.03.023

Bell S; Dean J; Gilks C; Boyd MA; Fitzgerald L; Mutch A; Baker P; Neilsen G; Gartner CE, 2017, 'Tobacco harm reduction with vaporised nicotine (THRiVe): The study protocol of an uncontrolled feasibility study of novel nicotine replacement products among people living with HIV who smoke', International Journal of Environmental Research and Public Health, 14, http://dx.doi.org/10.3390/ijerph14070799

Boyd MA, 2017, 'Body composition substudy of the SECOND-LINE study – Author's reply', The Lancet HIV, 4, pp. e240, http://dx.doi.org/10.1016/S2352-3018(17)30093-0

Rhee SY; Varghese V; Holmes SP; Van Zyl GU; Steegen K; Boyd MA; Cooper DA; Nsanzimana S; Saravanan S; Charpentier C; de Oliveira T; Etiebet MAA; Garcia F; Goedhals D; Gomes P; Günthard HF; Hamers RL; Hoffmann CJ; Hunt G; Jiamsakul A; Kaleebu P; Kanki P; Kantor R; Kerschberger B; Marconi VC; D'amour Ndahimana J; Ndembi N; Ngo-Giang-Huong N; Rokx C; Santoro MM; Schapiro JM; Schmidt D; Seu L; Sigaloff KCE; Sirivichayakul S; Skhosana L; Sunpath H; Tang M; Yang C; Carmona S; Gupta RK; Shafer RW, 2017, 'Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration', EBioMedicine, 18, pp. 225 - 235, http://dx.doi.org/10.1016/j.ebiom.2017.03.024

Aung NM; Hanson J; Kyi TT; Htet ZW; Cooper DA; Boyd MA; Kyi MM; Saw HA, 2017, 'HIV care in Yangon, Myanmar; successes, challenges and implications for policy', AIDS Research and Therapy, 14, pp. 10, http://dx.doi.org/10.1186/s12981-017-0137-z

Lau A; Kong F; Fairley CK; Donovan B; Chen M; Bradshaw C; Boyd M; Amin J; Timms P; Tabrizi S; Regan DG; Lewis DA; McNulty A; Hocking JS, 2017, 'Treatment efficacy of azithromycin 1 g single dose versus doxycycline 100 mg twice daily for 7 days for the treatment of rectal chlamydia among men who have sex with men - a double-blind randomised controlled trial protocol', BMC Infectious Diseases, 17, pp. 35, http://dx.doi.org/10.1186/s12879-016-2125-7

Boyd MA; Amin J; Mallon PWG; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA, 2017, 'Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study', The Lancet HIV, 4, pp. e13 - e20, http://dx.doi.org/10.1016/S2352-3018(16)30189-8

Petoumenos K; Choi JY; Hoy J; Kiertiburanakul S; Ng OT; Boyd M; Rajasuriar R; Law M; Han A, 2017, 'CD4:CD8 ratio comparison between cohorts of HIV-positive Asians and Caucasians upon commencement of antiretroviral therapy', Antiviral Therapy, 22, pp. 659 - 668, http://dx.doi.org/10.3851/IMP3155

Wright E; Grulich A; Roy K; Boyd M; Cornelisse V; Russell D; O'Donnell D; Whittaker B; Crooks L; Zablotska I, 2017, 'Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines', Journal of Virus Eradication, 3, pp. 168 - 184, http://dx.doi.org/10.1016/s2055-6640(20)30338-1

Boyd M; Cooper D; Crock EA; Crooks L; Giles ML; Grulich A; Lewin SR; Nolan D; Yarwood T, 2016, 'Sexual transmission of HIV and the law: An Australian medical consensus statement', Medical Journal of Australia, 205, pp. 409 - 412, http://dx.doi.org/10.5694/mja16.00934

Zaunders J; Danta M; Bailey M; Mak G; Marks K; Seddiki N; Xu Y; Templeton DJ; Cooper DA; Boyd MA; Kelleher AD; Koelsch KK, 2016, 'CD4+ T follicular helper and IgA+ B cell numbers in gut biopsies from HIV-infected subjects on antiretroviral therapy are similar to HIV-uninfected individuals', Frontiers in Immunology, 7, pp. 438, http://dx.doi.org/10.3389/fimmu.2016.00438

Lam EP; Moore CL; Gotuzzo E; Nwizu C; Kamarulzaman A; Chetchotisakd P; Van Wyk J; Teppler H; Kumarasamy N; Molina JM; Emery S; Cooper DA; Boyd MA, 2016, 'Antiretroviral resistance after first-line antiretroviral therapy failure in diverse HIV-1 subtypes in the SECOND-LINE study', AIDS Research and Human Retroviruses, 32, pp. 841 - 850, http://dx.doi.org/10.1089/aid.2015.0331

Achhra AC; Mwasakifwa G; Amin J; Boyd MA, 2016, 'Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis', The Lancet HIV, 3, pp. e351 - e360, http://dx.doi.org/10.1016/S2352-3018(16)30015-7

Lambert-Niclot S; George EC; Pozniak A; White E; Schwimmer C; Jessen H; Johnson M; Dunn D; Perno CF; Clotet B; Plettenberg A; Blaxhult A; Palmisano L; Wittkop L; Calvez V; Marcelin AG; Raffi F; Dedes N; Chěne G; Allavena C; Autran B; Antinori A; Bucciardini R; Vella S; Horban A; Arribas J; Babiker AG; Boffito M; Pillay D; Pozniak A; Franquet X; Schwarze S; Grarup J; Fischer A; Richert L; Wallet C; Diallo A; Molina JM; Saillard J; Moecklinghoff C; Stellbrink HJ; Van Leeuwen R; Gatell-Artigas JM; Sandstrom E; Flepp M; Ewings F; George EC; Hudson F; Pearce G; Quercia R; Rogatto F; Leavitt R; Nguyen BY; Goebel F; Marcotullio S; Kaur N; Sasieni P; Spencer-Drake C; Peto T; Miller V; Arnault F; Boucherie C; Jean D; Paniego V; Paraina F; Rouch E; Soussi M; Taieb A; Termote M; Touzeau G; Cursley A; Dodds W; Hoppe A; Kummeling I; Pacciarini F; Paton N; Russell C; Taylor K; Ward D; Aagaard B; Eid M; Gey D; Jensen BG; Jakobsen ML; Jansson PO; Jensen K; Joensen ZM; Larsen EM; Pahl C; Pearson M; Nielsen BR; Reilev SS; Christ I; Lathouwers D; Manting C; Mendy BY; Metro A; Couffin-Cadiergues S; Knellwolf AL, 2016, 'Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: Raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART', Journal of Antimicrobial Chemotherapy, 71, pp. 1056 - 1062, http://dx.doi.org/10.1093/jac/dkv427

Boyd MA; Cooper DA, 2016, 'Tenofovir alafenamide: safer, but questions remain', The Lancet HIV, 3, pp. e148 - e149, http://dx.doi.org/10.1016/S2352-3018(16)00039-4

Arts E; Boyd M, 2016, 'Reviewer acknowledgement.', AIDS Res Ther, 13, pp. 13, http://dx.doi.org/10.1186/s12981-016-0097-8

Boyd MA; Cooper DA, 2016, 'Novel antiretroviral agents and universal access to HIV care', The Lancet HIV, 3, pp. e2 - e3, http://dx.doi.org/10.1016/S2352-3018(15)00244-1

Alvarez E; Belloso WH; Boyd MA; Inkaya AC; Hsieh E; Kambugu A; Kaminski G; Martinez E; Stellbrink HJ; Walmsley S; Brown TT; Mallon PWG, 2016, 'Which HIV patients should be screened for osteoporosis: An international perspective', Current Opinion in HIV and AIDS, 11, pp. 268 - 276, http://dx.doi.org/10.1097/COH.0000000000000269

Arts E; Boyd M, 2016, 'Reviewer acknowledgement.', AIDS Res Ther, 13, pp. 13, http://dx.doi.org/10.1186/s12981-016-0097-8

Amin J; Boyd MA; Kumarasamy N; Moore CL; Losso MH; Nwizu CA; Mohapi L; Kerr SJ; Sohn AH; Teppler H; Renjifo B; Molina JM; Emery S; Cooper DA, 2015, 'Erratum: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection (PLoS ONE (2015)10:2 (e0118228) Doi: 10.1371/journal.pone.0118228 ))', PLoS ONE, 10, pp. e0140623, http://dx.doi.org/10.1371/journal.pone.0140623

Boyd MA; Cooper DA, 2015, 'The LATTE study: A provocative brew', The Lancet Infectious Diseases, 15, pp. 1116 - 1117, http://dx.doi.org/10.1016/S1473-3099(15)00224-8

Templeton DJ; Wright ST; McManus H; Lawrence C; Russell DB; Law MG; Petoumenos K; Ellis D; Bloch M; Agrawal S; Vincent T; Allen D; Smith D; Allardice K; Baker D; Odgers E; O'Connor CC; Phan S; Jackson E; McCallum K; Grotowski M; Ryder N; Taylor S; Cooper D; Carr A; Lee F; McRae K; Hesse K; Finlayson R; Gupta S; Varma R; Shakeshaft J; Brown K; McGrath V; Halligan S; Arvela N; Wray L; Thng C; Foster R; Lu H; Couldwell D; DSmith E; Furner V; Fernando S; Dubbo ; Watson J; Mulhall B; Wright S; Bendall C; Boyd M; Gunathilake M; Payne R; O'Sullivan M; White S; Russell D; Joslin J; Cashman C; Sowden D; Taing K; McGill K; Orth D; Youds D; Kelly M; Rowling D; Latch N; Warzywoda E; Dickson B; Donohue W; Moore R; Edwards S; Boyd S; NRoth J; Lau H; Read T; Silvers J; Zeng W; Hoy J; Watson K; Bryant M; Price S; Woolley I; Giles M; Korman T; Williams J; Nolan D; Guelfi G; Mills G; Wharry C; Raymond N; Bargh K; Morwood K; Roth N; Choong K; Cooper D; Han A, 2015, 'Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD)', BMC Infectious Diseases, 15, pp. 326, http://dx.doi.org/10.1186/s12879-015-1051-4

Amin J; Becker S; Belloso W; Boffito M; Cooper D; Crabtree-Ramirez B; Duncombe C; Foulkes S; Hill A; Jessen H; Kumar S; Lee MP; Nwizu C; Read T; Rooney J; Schaffer K; Shahar E; Winston A; Wolff M; Young B; Abela C; Avihingsanon A; Boyd M; Carey D; Clarke A; Courtney-Vega K; Delfino M; Donaldson A; Emery S; Espinosa N; Johannesen T; Lin E; Losso M; Moricz A; Pett S; Phanupak P; Puls R; Pussadee K; Sutheerasak P; Tomlins L; Ubolyam S; bin Raja Azwa RIS; Bissio E; Calanni L; Chetchotisakd P; Doong N; Elliott J; Gazzard B; Kelly M; Laplume H; del Carmen Luna N; Lupo S; Messina OG; Mohapi L; Moore R; Nolan D; Orrell C; Perez C; Phanuphak P; Rockstroh J; Rowling D; Supparatpinyo K; Smith D; Villanueva JA; Vlahakis E; Kelleher T; Cunningham P; Merlin K; Yeung J; Shaik A; Fsadni B; Carrera A; Lograsso M; Gulick R; Dunn D; Dolan M; Emery S; Kelleher A, 2015, 'Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study', The Lancet Infectious Diseases, 15, pp. 793 - 802, http://dx.doi.org/10.1016/S1473-3099(15)70060-5


Back to profile page